資訊
Molecular Partners於ASCO 2024年會議上發表了MP0317 (FAP X CD40 DARPin)單獨用於晚期實體腫瘤患者的第1期試驗積極數據。
Molecular Partners在ASCO 2024年會議上提出了MP0317 CD40激活劑第1期試驗的最終數據。研究包括46名晚期實體腫瘤患者，展示了良好的安全性和有希望的療效。MP0317被證明定位在腫瘤微環境(TME)內，激活免疫細胞而無全身毒性。該藥物的安全檔案可控，常見的副作用是輕微疲勞和輸液反應。一位患者表現出未確認的局部反應，而有14位患者維持疾病穩定。這些發現鼓勵進一步的臨床試驗，特別是在組合療法中。
Molecular Partners在ASCO 2024年會議上提出了MP0317 CD40激活劑第1期試驗的最終數據。研究包括46名晚期實體腫瘤患者，展示了良好的安全性和有希望的療效。MP0317被證明定位在腫瘤微環境(TME)內，激活免疫細胞而無全身毒性。該藥物的安全檔案可控，常見的副作用是輕微疲勞和輸液反應。一位患者表現出未確認的局部反應，而有14位患者維持疾病穩定。這些發現鼓勵進一步的臨床試驗，特別是在組合療法中。
2024年06月01日-上午05:00
MP0317定位和在腫瘤微環境中激活免疫細胞所支持的作用機制
在所有測試劑量水平上觀察到的良好且可控的安全檔案
經過藥物動力學和藥效學支持的每週和三週一次的劑量方案已確立
數據支持在組合療法中進一步對MP0317進行臨床評估
2024年06月01日-SWITZERLAND-SCHLIEREN的ZURICH和MASSACHUSETTS州CONCORD (GLOBE NEWSWIRE) - 根據Art. 53 LR的臨時公告 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, held in Chicago, IL, USA. MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP) which is expressed in high amounts around tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies.
MP0317定位和在腫瘤微環境中激活免疫細胞所支持的作用機制
在所有測試劑量水平上觀察到的良好且可控的安全檔案
經過藥物動力學和藥效學支持的每週和三週一次的劑量方案已確立
數據支持在組合療法中進一步對MP0317進行臨床評估
2024年06月01日-SWITZERLAND-SCHLIEREN的ZURICH和MASSACHUSETTS州CONCORD (GLOBE NEWSWIRE) - 根據Art. 53 LR的臨時公告 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, held in Chicago, IL, USA. MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP) which is expressed in high amounts around tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies.
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
